| Literature DB >> 19189989 |
Jue Zhou1, Fan Qu, Xisheng Sang, Xiaotong Wang, Rui Nan.
Abstract
The objective of this study is to explore the effects of acupuncture and auricular acupressure in relieving menopausal hot flashes of bilaterally ovariectomized Chinese women. Between May 2006 and March 2008, 46 bilaterally ovariectomized Chinese women were randomized into an acupuncture and auricular acupressure group (n = 21) and a hormone replacement therapy (HRT) group (Tibolone, n = 25). Each patient was given a standard daily log and was required to record the frequency and severity of hot flashes and side effects of the treatment felt daily, from 1 week before the treatment started to the fourth week after the treatment ended. The serum levels of follicle stimulating hormone (FSH), LH and E(2) were detected before and after the treatment. After the treatment and the follow-up, both the severity and frequency of hot flashes in the two groups were relieved significantly when compared with pre-treatment (P < .05). There was no significant difference in the severity of hot flashes between them after treatment (P > .05), while after the follow-up, the severity of hot flashes in the HRT group was alleviated more. After the treatment and the follow-up, the frequency of menopausal hot flashes in the HRT group was reduced more (P < .05). After treatment, the levels of FSH decreased significantly and the levels of E(2) increased significantly in both groups (P < .05), and they changed more in the HRT group (P < .05). Acupuncture and auricular acupressure can be used as alternative treatments to relieve menopausal hot flashes for those bilaterally ovariectomized women who are unable or unwilling to receive HRT.Entities:
Year: 2010 PMID: 19189989 PMCID: PMC3137273 DOI: 10.1093/ecam/nep001
Source DB: PubMed Journal: Evid Based Complement Alternat Med ISSN: 1741-427X Impact factor: 2.629
Figure 1Study design.
The baseline characteristics of the participants.
| Item | Acupuncture and auricular acupressure group ( | HRT group ( |
|---|---|---|
|
| ||
| Age (years) | 41.6 ± 5.8 | 42.8 ± 4.1 |
| Time since ovariectomy (years) | 1.3 ± 0.4 | 1.2 ± 0.5 |
| Married/living as married | 14 (73.7%) | 18 (75.0%) |
| Divorced/separated | 4 (21.1%) | 5 (20.8%) |
| Never married | 1 (5.3%) | 1 (4.2%) |
| Women with children | 14 (73.7%) | 14 (58.3%) |
|
| ||
|
| ||
| Urban | 12 (63.2%) | 21 (87.5%) |
| Suburban | 3 (15.8%) | 2 (8.3%) |
| Small town | 2 (10.5%) | 0 |
| Rural | 2 (10.5%) | 1 (4.2%) |
|
| ||
|
| ||
| Full-time employment | 8 (42.1%) | 18 (75.0%) |
| Part-time employment | 5 (26.3%) | 2 (8.3%) |
| Registered unemployed | 3 (15.8%) | 2 (8.3%) |
| Retired | 3 (15.8%) | 2 (8.3%) |
|
| ||
|
| ||
| Bilateral tubal-ovarian cyst | 2 (10.5%) | 8 (33.3%) |
| Bilateral tubal-ovarian abscess | 3 (15.8%) | 2 (8.3%) |
| Malignant tumor of uterus and/or ovary | 3 (15.8%) | 2 (8.3%) |
| Benign tumor of uterus and/or ovary | 2 (10.5%) | 3 (12.5%) |
| Removing the need for contraception | 1 (5.3%) | 2 (8.3%) |
| Prophylactic ovariectomy | 2 (10.5%) | 1 (4.2%) |
| Bilateral severe ovarian endometriosis | 3 (15.8%) | 2 (8.3%) |
| Cessation of menstruation | 2 (10.5%) | 2 (8.3%) |
| Other | 1 (5.3%) | 2 (8.3%) |
| Duration of the menopausal hot flashes (year) | 1.1 ± 0.5 | 1.3 ± 0.4 |
The severity and frequency of hot flashes and the serum levels of FSH, LH and E2.
| Item | Acupuncture and auricular acupressure group ( | HRT group ( |
|---|---|---|
| Hot flash severity | ||
| Pre-treatment | 14.71 ± 3.81 (95% CI 12.96–16.52) | 15.28 ± 4.06 (95% CI 13.53–16.96) |
| Post-treatment | 3.86 ± 0.84* (95% CI 3.40–4.45) | 3.71 ± 0.65* (95% CI 3.44–3.97) |
| Follow-up | 4.45 ± 0.90∗,# (95% CI 3.92–4.95) | 3.25 ± 0.34* (95% CI 3.00–3.33) |
|
| ||
| Hot flash frequency | ||
| Pre-treatment | 14.21 ± 2.42 (95% CI 13.37–15.88) | 15.11 ± 4.96 (95% CI 13.04–17.30) |
| Post-treatment | 10.32 ± 3.13∗,# (95% CI 8.80–12.32) | 7.48 ± 2.69* (95% CI 6.33–8.59) |
| Follow-up | 7.69 ± 1.48∗,# (95% CI 7.12–8.63) | 5.58 ± 1.64* (95% CI 4.86–6.22) |
|
| ||
| FSH (mIU/mL) | ||
| Pre-treatment | 51.5 ± 13.9 (95% CI 46.7–58.7) | 53.0. ± 14.3 (95% CI 46.9–59.0) |
| Post-treatment | 40.4 ± 9.6∗,# (95% CI 34.6–44.5) | 22.7 ± 5.1* (95% CI 20.6–24.8) |
|
| ||
| LH (mIU/mL) | ||
| Pre-treatment | 33.7 ± 6.4 (95% CI 30.2–37.0) | 32.9 ± 7.1 (95% CI 29.9–35.9) |
| Post-treatment | 31.9 ± 5.7# (95% CI 28.6–34.9) | 15.6 ± 4.8* (95% CI 13.6–17.6) |
|
| ||
| E2 (pg/mL) | ||
| Pre-treatment | 37.1 ± 8.9 (95% CI 32.0–41.5) | 39.4 ± 7.0 (95% CI 36.4–42.3) |
| Post-treatment | 45.4 ± 7.3∗,# (95% CI 41.7–49.4) | 71.5 ± 13.4* (95% CI 65.8–77.1) |
FSH, follicle stimulating hormone; LH, luteinizing hormone; E2, estradiol; CI, Confidence intervals. *P < .05, compared with pre-treatment in the same group. P < .05, compared with the HRT group.